Guangzhou Kingmed Diagnostics Group's declining ROCE trend is worrying, indicating potential loss of competitive edge or market share. Despite increased capital deployment, returns and sales are decreasing. High investor expectations are reflected in the 144% stock rise over five years, but current trends cast doubt on long-term performance.

Despite weakened growth prospects, the stock trades at a market-typical P/E. Investors might face future letdowns if the P/E drops in line with the growth outlook. The stock price risks falling given the lukewarm earnings outlook paired with slower than market growth.

Concerns grow over diminishing return on high capital in Guangzhou Kingmed Diagnostics. Despite weak fundamentals, the stock gained 228% over 5 years. Exercise caution due to shaky fundamentals.